Disease Archive

Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration

Treatment for Dry Eye Disease Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration Print this page WALTHAM, Mass.–(BUSINESS WIRE)–Dec. 26, 2018– Kala Pharmaceuticals, …